STUDY PURPOSE: To assess the evidence regarding the use of corticosteroids for fatigue among patients with advanced cancer

• FINAL NUMBER STUDIES INCLUDED = 4
• TOTAL PATIENTS INCLUDED IN REVIEW = Not provided
• SAMPLE RANGE ACROSS STUDIES: Not provided
• KEY SAMPLE CHARACTERISTICS: All studies were of patients with advanced disease with minimal life expectancy.

SAMPLE RANGE ACROSS STUDIES, 

• PHASE OF CARE: End-of-life care
• APPLICATIONS: Palliative care

All studies reported improvement in patient-reported fatigue. Gaps were noted in information regarding side effects and the specifics of the dosage, etc., of the intervention.

Corticosteroids may improve fatigue in patients with advanced cancer, but potential adverse side effects have not been examined well.

• Limited number of studies
• No details of included studies, such as sample sizes, etc., were provided.

Corticosteroids may improve fatigue in patients with cancer, but insufficient information about adverse effects exists. Steriods should not be used for a long duration—an intervention that may be useful for patients who desire short-term improvement in feelings of fatigue to participate in family events, etc.

 To determine the effect of acupuncture on hot flash (HF) frequency and intensity, quality of life, and sleep quality in patients undergoing hormonal therapy for prostate cancer.

Men with HF scores greater than four who received androgen-depriving therapy underwent acupuncture with electrostimulation biweekly for four weeks then weekly for six weeks using a predefined treatment plan. Patients completed a Hot Flash Diary daily for seven days prior to treatment then daily throughout the study.

• The sample was comprised of 22 males with prostate cancer.  
• Median age was 71 years.
• Patients were undergoing androgen deprivation therapy.

The study enrolled men with prostate cancer who were treated with bilateral orchiectomy, gonadotropin-releasing hormone agonist, or antagonists with or without antiandrogen therapy. The sample group reported at least four HFs per day. They could not be receiving concurrent chemotherapy, estrogens, progesteronal agents, or gabepentin. They had to be off of selective serotonin reuptake inhibitor (SSRI) class antidepressants for at least two weeks; however, the SSRI prohibition was removed after 16 patients were enrolled to speed accrual. Patients with pacemakers or other electrical devices were excluded.

• Single site   
• Outpatient   
• Sweden

• Patients were undergoing the active treatment phase of care.
• The study has clinical applicability for late effects and survivorship and elderly care.

The study used an open-label, single arm, phase II design.

• Hot Flash Related Daily Interference Scale (HFDIS)
• Pittsburgh Sleep Quality Index (PSQI)
• Short Form 36-item Health Survey (SF-36)
• Blood samples plasma calcitonin gene-related peptide (CGRP)
• Urine samples 5-HIAA
• Hot Flash Diary

Acupuncture treatment was administered twice weekly, with an attempt to use the same practitioner throughout the treatment period. Specific acupuncture sites were used in all patients. The HF score was calculated from the Hot Flash Diary, and each HF was calculated to determine severity. The severity-adjusted HF scores were summed for seven days. Biomarkers were assessed at baseline; 2, 4, 6, and 10 weeks of treatment; and again after 6 weeks. The mean HF score was reduced after four weeks of therapy, then reduced to 52% of baseline at eight weeks. The HFDISs were available for 21 of the improved patients. The PSQI was available for 19 patients, but there was no statistical significance noted from baseline to after 10 weeks of treatment. No improvement in overall vitality was measured by the SF-36. No significant adverse effects were noted. Regarding the biomarkers, no change in the serum serotonin levels was noted for any patient. Urinary 5-HIAA had a nonsignificant trend toward reduced 5-HIAA concentrations, with the nonresponders (two patients) having an increase over time. The nonresponders' 5-HIAA concentrations were 129% of baseline, whereas the responders at week 10 showed 73.3% of baseline concentrations. The CGRP levels baseline sample results were so diverse that subsequent samples obtained during and posttreatment detected no meaningful differences. The variability in the CGRP samples reduced the statistical power of the study to detect differences.

The study suggested that acupuncture may be an active nonpharmacologic option for patients with prostate cancer experiencing HFs while undergoing hormonal treatment.

• The study had a small sample size, with less than 30 patients.
• Hot flash Diaries were incomplete beyond week 8, so the severity of hot flashes was not calculable past the time point proposed.
• The variability in the CGRP samples reduced the statistical power of the study to detect differences.

Further research is needed in the use of acupuncture in reducing HF scores and improving sleep quality in prostate cancer survivors. Further research may also be needed  to determine if differences exist between genders for HF distress/occurrence and sleep quality, which may provide some direction for extrapolating research results with either gender group.

STUDY PURPOSE: To review the evidence for axillary reverse mapping (ARM) and discuss the feasibility, safety, and relevance of this procedure

TYPE OF STUDY: General review/"semi" systematic

• FINAL NUMBER STUDIES INCLUDED = 31 
• TOTAL PATIENTS INCLUDED IN REVIEW = 2,747
• SAMPLE RANGE ACROSS STUDIES: 23–327
• KEY SAMPLE CHARACTERISTICS: All had breast cancer surgery involving ARM

PHASE OF CARE: Active antitumor treatment

Evidence shows a wide range of visualization rates from 20%–90% and notes that rates are lower with sentinel lymph node biopsy (SNLB) than with axillary lymph node dissection (ALND). The definition of successful ARM, the volume of blue dye used, and the experience of the surgeon varied, all of which may affect these rates. Blue dye, flourescent dye, and radioisotopes have been used for visualization. No adverse events from the procedures have been noted. At present, no axillary recurrence has been reported in patients in whom lymph nodes were preserved. ARM may contribute to a reduction in upper extremity lymphedema, although current evidence is not strong enough to draw firm conclusions.

The preservation of lymph nodes with ARM appears to be safe and may contribute to a reduction in the incidence of upper extremity lymphedema.

• No quality evaluation
• Most studies had a relatively short follow-up time frame.

The preservation of axillary lymph nodes in women undergoing surgery for breast cancer with ARM appears to be safe. The evidence suggests that ARM with lymph node preservation may reduce the prevalence of arm lymphedema; however, multiple limitations in the available evidence exist. Ongoing research of the long-term effects on patient outcomes is needed and underway.

To evaluate evidence on the effectiveness of the peripherally acting mu-receptor antagonists alvimopan and methylnaltrexone in the management of opioid-induced constipation.

Databases searched were Ovid MEDLINE, Biological Abstracts, BIOSIS Previews, CINAHL, Evidence-Based Medicine Reviews (EBMR) (Cochrane Database of Systematic Reviews, ACP [American College of Physicians] Journal Club, Database of Abstracts of Reviews of Effectiveness [DARE], and the Cochrane Central Register of Controlled Trials [1966-May 2005]), PubMed (1996-May 2005), CancerLit (1963-June 2005), and Embase (1980-May 2002). A hand search also was conducted on bibliographies of books about palliative care.  From that hand search, reference citations concerning constipation were identified to find additional clinical trials to include in the review.

Search keywords were constipation, intestinal obstruction, opioid bowel dysfunction, opioid related constipation, opioid-related disorders, peripherally acting opioid antagonist, opioid antagonist, opioid mu receptors, narcotic antagonists/naltrexone, methylnaltrexone, and alvimopan.

Studies were included in the review if

• The trial population comprised adults with opioid-related constipation who (a) had chronic pain and were being treated with an opioid regimen, (b) were on methadone maintenance programs, or (c) were healthy volunteers used as models to reproduce the condition of real patients.
• The sample size was at least 10 participants.
• The intervention treatment was with methylnaltrexone or alvimopan.
• The outcome measures of prevention or reduction of constipation and the incidence of adverse events were addressed.

Studies were excluded if they had a small sample size (fewer than 10 participants) or used the Rome Diagnostic Criteria to define constipation.

Ten studies were appropriate for this review. However, four of the 10 had two or three parts performed in different populations or using different dosing regimens. The differing parts were treated as different studies and assessed individually, yielding 15 studies (10 randomized controlled trials and five phase II studies addressing dose and toxicity).

• Study groups ranged in size from 11 to 168 participants, for a total of 605 participants in all 15 studies.
• Seven studies included healthy volunteers, two included members of methadone maintenance programs, and three included both members of methadone maintenance programs and patients with chronic pain.
• One study looked at patients receiving opioids for acute pain and two included hospice patients.

This systematic review looked mainly at the efficacy of using the peripherally acting opioid antagonists methylnaltrexone (nine studies) and alvimopan (six studies) in managing opioid-induced constipation. Internal validity of the studies was high, indicating methylnaltrexone and alvimopan may be effective in relieving opioid-induced constipation. However, most study participants were healthy volunteers or members of methadone programs.

• The studies in this review addressed the efficacy of methylnaltrexone and alvimopan. However, most study participants were healthy volunteers or members of methadone programs. The question arises as to whether the effectiveness of those drugs would hold true in other populations.
• Additional research is needed to assess the effectiveness of methylnaltrexone and alvimopan in patients with cancer. Not all of the studies addressed the effects of those peripherally acting antagonists on pain control and withdrawal. Of the 15 studies, five reported no effect on pain and seven reported no withdrawal effects. The effects of those drugs on pain and withdrawal require additional study.

To a conduct a systematic review of the published literature related to the effectiveness of cancer-related lymphedema management in palliative care

Databases searched were PubMed, MEDLINE, CINAHL, Cochrane Library databases, PapersFirst, Proceedings First, Worldcat, PEDro, National Guidelines Clearing House, ACP Journal Club, and Dare.

Search keywords were lymphedema (lymphoedema, lymphodema, elephantiasis, swelling, edema, and oedema) and palliative care (advanced disease and metastatic cancer).

Studies were included in the reivew if they related to lymphedema management in the setting of palliative care, including randomized controlled trials, cohort studies, case-control studies, meta-analyses, and systematic reviews.

Studies were excluded if they

• Had no available English translation
• Did not evaluate an intervention
• Did not address lymphedema in the palliative care period
• Were abstracts only, letters to the editor, cross-sectional studies, qualitative studies, or general lymphedema overviews.

• Using the search terms, 31 references were retrieved.
• The research was evaluated using the PEP categories of levels of evidence.

• Eleven studies were included.
• Samples sizes ranged from 1–90 across studies.
• Samples included patients with various types of advanced or metastatic cancer and lymphedema.

Patients were undergoing end-of-life and palliative care.

The study identified four categories of lymphedema in the palliative care settings.

• Five case studies addressed closed-controlled subcutaneous drainage.
• One retrospective study dealt with manual lymphatic drainage (MLD).
• Two case studies looked at compression therapy.
• Three case studies addressed complete decongestive therapy (CDT).

Only a few studies (4 out of 11) included objective measures of outcomes. All studies were in the category of \"Effectiveness Not Established\" assessed by the Oncology Nursing Society Putting Evidence Into Practice classification.

A lack of rigorously designed clinical research studies have been conducted pertaining to the treatment of lymphedema in patients with advanced or metastatic cancer.

• Articles published prior to January 2004 were not included in this systematic review. The authors did not provide an explanation for this.
• Articles with no available English translation were excluded. This exclusion criterion indicates that articles from non-English countries (e.g., Germany, China, and India) were not reviewed; however, the authors did not state the possible number of these non-English articles.

This systematic review indicated that the identified procedures (closed-controlled subcutaneous drainage, MLD, compression therapy, and CDT) are relatively safe. Nurses may consider recommending these procedures to individuals with lymphedema and advanced or metastatic cancer. Nurse scientists need to conduct more rigorously designed studies to test the effectiveness of management of cancer-related lymphedema in palliative care.

To evaluate the efficacy of adding aprepitant to an antiemetic regimen for the prevention of chemotherapy-induced nausea and vomiting (CINV)

Participants received aprepitant at 125 mg orally on day 1 followed by 80 mg orally at 24 and 48 hours after the initial dose of aprepitant. Ondansetron was given at 16 mg orally on day 1, and dexamethasone was given at at 12 mg orally on day 1 and at 8 mg orally on days 2–4. Breakthrough medications were used as needed. There was no comparison or control group. To evaluate nausea and vomiting, patients were assessed four to six times per day for the presence or absence of vomiting, the frequency of emetic episodes, the need for breakthrough antiemetic medication, and a nausea score provided by the nurse. Mean nausea scores were assessed every 24 hours beginning 24 hours after chemotherapy and continuing 120 hours after chemotherapy.

• N = 26  
• MEAN AGE = 59.3 years (no range given)
• MALES: 65%, FEMALES: 35%
• KEY DISEASE CHARACTERISTICS: Multiple myeloma and autologous stem cell transplant
• OTHER KEY SAMPLE CHARACTERISTICS: High-dose melphalan

• SITE: Not specified
• SETTING TYPE: Not specified    
• LOCATION: Not specified

• PHASE OF CARE: Active antitumor treatment

Prospective, single-arm study

• Nausea scores were determined using a linear analog scale (0–10).

Complete response was defined as no more than one emetic episode during the evaluation period. Of the 26 participants, 25 (96%) completely responded and needed no additional breakthrough medication. Twenty-four (92%) had no documented emetic episodes during the study period. Some degree of nausea was reported by 23 out of 26 (88%) patients, and the mean nausea score for the entire group during the study period was 0.7 (range = 0–10).

Adding aprepitant to a standard antiemetic regimen may result in lower rates of CINV associated with high-dose melphalan and stem cell transplant.

• Small sample (< 30)
• Risk of bias (no control group)

Adding aprepitant to standard antiemetic regimens may result in better controlled CINV. However, with such a small sample size and no comparison group, attributing these results to the intervention is difficult.

To report the efficacy of Hydrosorb versus water-based spray (control) to treat G1-2 radiodermatitis in patients with early stage breast cancer (BC) treated with normo-fractionated radiotherapy (RT)

• Patients were randomized to either the (a) Hydrosorb arm or the (b) placebo arm if they had the presence of grade 1 or grade 2 radiodermatitis.
• Baseline colorimetric measurement was performed on healthy skin on day 0.
• Local placement of Hydrosorb was done by the research nurse for the first time with subsequent education on how to apply at home. 
• Study observations were conducted on days 7,14, 21, and 28.
• All patients were instructed in skin care: use of mild soap for cleansing and daily moisturizer, avoidance of pools and sunlight, use of razors or deodorant
• Patients were removed from the study for grade 3 or 4 dermatitis.

• N = 278 in intention to treat analysis
• MEDIAN AGE = 53 years
• AGE RANGE = 21–86 years
• MALES: Not stated  
• FEMALES: Not stated
• KEY DISEASE CHARACTERISTICS: All patients had breast cancer. Three patients in the Hydrosorb arm had diabetes (2.1%), and six patients in the placebo group (4.4%).
• OTHER KEY SAMPLE CHARACTERISTICS: Age, body mass index, tobacco use, diabetes, neoadjuvant chemotherapy, radiodermatitis grade, median dose, medial colorimetric value, colorimetric value in two categories, median surface, pain, concurrent hormonal treatment

• SITE: Multicenter
• SETTING TYPE: Hospital
• LOCATION: France

PHASE OF CARE: Active treatment

Randomized, prospective, open-label, placebo-controlled study

• Dermatology Life Quality Index (DLQI) questionnaire 
• Colorimetric evaluation (chromameter)
• Visual analog scale (VAS) 
• Common Terminology Criteria for Adverse Events (CTCAE), version 3

• Sixty (49%) treatment interruptions/failures occurred in Hydrosorb arm versus 62 (51%) in the control arm (p = 0.58).
• Twenty-four patients discontinued RT for local care.
• No colorimetric difference existed between the two arms (p = 0.21).
• The average absolute reduction of colorimetric levels between day 28 and day 0 was 4. 
• The median surface area of radiation dermatitis zone on D28 was 4.04 (Hydrosorb) and 4 (placebo).
• The median VAS on D28 was 2 in both arms.
• Forty-eight patients in the Hydrosorb arm had a VAS score greater than 2 versus 51 patients in the placebo arm (i.e., 34% and 38%, respectively) (p = 0.45).
• Significant reduction of pain was observed on D7 (p = 0.04) and D21 (p = 0.01) in the Hydrosorb arm.
• Median quality of life (QOL) per DLQI on D28 was 5 in both arms.
• Sixty patients in the Hydrosorb arm and 55 patients in the placebo arm had moderately to severely altered QOL (p = 0.76).
• Skin care was considered to be satisfactory for 125 patients in the Hydrosorb arm (88%) and 116 patients in the placebo arm (85%) (p = 0.059).

No significant difference existed between Hydrosorb and placebo in the treatment of acute radioinduced dermatitis. A trend in improvement in pain was observed with the use of Hydrosorb; however, any additional treatment given for pain, which was allowed, was not described.

The ingredients of the patients' applied moisturizer were not defined and could have altered skin physiology in both arms. The frequency of Hydrosorb application was not defined. No actual grading of dermatitis existed per se. Changes in local treatment were allowed, but no information was provided regarding what additional treatments were done.

This study did not show that Hydrosorb was effective in preventing the increase of radiodermatitis severity. Patient instructions used here included outdated information, such as the need to avoid use of deodorants. Very limited evidence shows that topical treatments effectively prevent radiodermatitis.

To investigate the efficacy of aprepitant in children and young adolescents receiving highly or moderately emetogenic chemotherapy who experienced uncontrollable emesis in previous cycles

This was a retrospective, observational analysis in children and adolescents aged greater than three years treated with aprepitant at a hospital in Belgium. Patients were identified through pharmacy records. Data on the use of antiemetics and emesis control were retrieved from pharmacy and nursing files. Emesis was defined as at least one episode of vomiting during the current chemotherapy cycle. Complete vomiting control was defined as no vomiting during the current cycle while incomplete control was defined as at least one episode of vomiting. The use of aprepitant was recorded and analyzed for each patient and for every chemotherapy cycle in which aprepitant was given.

• N = 20  
• AVERAGE AGE = 14 years (range = 8–16 years)
• MALES: 55%, FEMALES: 45%
• KEY DISEASE CHARACTERISTICS: Bone tumor, lymphoma, leukemia, malignant mesenchymal tumor, germ cell tumor, hepatocellular carcinoma, and relapsed nephroblastoma and neuroblastoma
• OTHER KEY SAMPLE CHARACTERISTICS: Two patients were younger than than 11 although aprepitant is used in patients older than 11.

• SITE: Single site    
• SETTING TYPE: Inpatient    
• LOCATION: Ghent University Hospital in Belgium

• PHASE OF CARE: Multiple phases of care
• APPLICATIONS: Pediatrics

Retrospective, observational analysis over three years 

• Demographic data, cancer type, chemotherapy treatment protocol, emetogenic level of the chemotherapy cycle, administration of antiemetics, and emesis control over 24 hours, after 24 hours, and overall were recorded.
• Emesis episodes (at least one during the chemotherapy cycle) and complete vomiting control (no vomiting during the current chemotherapy cycle) were endpoints.

Half the patients, representing a sizable percentage of episodes with complete emesis control, benefited from the use of aprepitant in combination with other antiemetics. This suggested the added value of aprepitant in patients receiving moderately or highly emetogenic cycles of chemotherapy, especially as all the included patients experienced uncontrollable emesis in previous cycles. Patients or parents with a positive experience with aprepitant asked for the availability of the product in subsequent cycles, which highlights its value.

• Small sample (< 30) 
• Risk of bias (no appropriate attentional control condition)  
• Risk of bias (sample characteristics)

Aprepitant achieved good results in preventing or reducing vomiting in children, which might improve compliance and patient and family satisfaction.

The objectives of the study were to

• Determine the effectiveness of nonpharmacologic and noninvasive interventions to relieve breathlessness in patients suffering from primary and secondary cancer, chronic obstructive pulmonary disease, interstitial lung disease, chronic heart failure, and motor neuron disease
• Find out which intervention strategies are available, which are effective, and which participant groups benefit most from which interventions.

• Databases searched were The Cochrane Central Register of Controlled Trials; MEDLINE; EMBASE; CINAHI; British Nursing Index; PsycINFO; Science Citation Index Expanded; AMED; The Cochrane Pain, Palliative, and Supportive Care Trials Register; The Cochrane Database of Systemic Reviews; and Database of Abstracts of Reviews of Effectiveness.
• After the initial search, reference lists from key articles, texts, and websites also were searched.
• Authors with research in progress were contacted for unpublished data.
• Search keywords were dyspnoea, shortness of breath, breathlessness, difficulty of breathing, or laboured breathing.
• Included were randomized controlled and controlled clinical trials, including quasi-randomised trials and trials with double-blinding assessing the effectiveness of nonpharmacologic and noninvasive interventions to relieve breathlessness in participants with advanced stages of cancer, chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), chronic heart failure (CHF), and motor neuron disease (MND).
• Studies were excluded if they examined any invasive interventions.
• Studies having the intervention compared against placebo or usual therapy were not included.

• Initially, 5,154 articles were retrieved; a final of 47 are included in this review.
• Two review authors assessed studies identified by the search for their relevance for inclusion.
• Breathlessness was validated by reliable rating scales such as visual analogue scales (VAS), numeric rating scales (NRS), categorical scales, and modified Borg scales.
• The Oxford Quality Scale was used to evaluate randomization, double blinding, description of withdrawal, and dropouts.
• The Method Score From Edwards was used for studies with less rigorous methodology.
• The Palliative Care National Institute of Clinical Excellence (NICE) guidelines were used to assess the grade of evidence.

The study reported on a sample of 2,532 participants in 47 studies categorized into single intervention or multi-component interventions.

The following single interventions were identified.

• Walking aids (seven studies)
• Distractive auditory stimuli (music) (six studies)
• Chest wall vibration (five studies)
• Acupuncture/acupressure (five studies)
• Relaxation (four studies)
• Neuro-electrical stimulation (three studies)
• Fan (two studies)

The following multi-component interventions were identified.

• Counseling and support (six studies)
• Breathing training (three studies)
• Counseling and support with breathing training (two studies)
• Case management (two studies)
• Psychotherapy (two studies)

A meta-analysis of the included studies was not possible due to hetereogeneity of the studies. Strong evidence suggests that neurologic muscular electrical stimulation and chest wall vibrations provide helpful relief of breathlessness in patients with COPD. However, the practical implications of the chest wall vibration interventions were only conducted in the respiratory laboratory. The evidence is moderately strong for walking aids having some benefits for patients with COPD with breathlessness by reducing the work of chest muscles. Moderate strength of evidence exists for breathing training being beneficial for breathless patients. Finally, not enough evidence exists to recommend usage of acupuncture, distractive auditory stimuli, relaxation, fan, counseling and support programs, or counseling and support programs in combination with relaxation and breathing training, case management, and psychotherapy.

Moderate evidence strength for walking aids and breathing retraining for COPD suggests these may be helpful interventions. Applicability in patients with cancer may be worth investigation.

• Nonpharmacologic interventions for breathlessness need further testing.
• Studies with sufficient sample size and power calculations are needed to be applicable to palliative care settings.
• In recent years, a significant research gap exists in cancer, ILD, CHF, and MND.
• The effectiveness of the chest wall vibration interventions should be retested outside the respiratory lab.
• The beneficial timing of neuro-electrical stimulation should be investigated and tested.
• Testing for whether acupressure or acupuncture alone or together has the best relief for breathlessness in patients is needed.
• More research is needed to study the long-term effect of nonpharmacologic interventions on ongoing problems in advanced disease until the end of life.
• Interventions should be developed for breathlessness at rest.
• Mixed approaches of interventions should be tested.
• New nonpharmacologic interventions related to breathless patients in advanced disease should be tested and investigated.

The objective of the study was to determine effectiveness and acceptance of use of a handheld fan to relieve breathlessness in patients with advance chronic obstructive pulmonary disease (COPD) and cancer.

Patients were randomly assigned to the fan or control groups. Control patients were given a wristband and instructed to wear it constantly and pull it at short intervals when breathless. Patients in the intervention group were given a handheld fan, shown how to use it (aimed at the central part of the face), and given a booklet with instructions for use. Data were collected at baseline and by monthly postal questionnaires for six months or until the patient died.

• The study reported on a sample of 36 evaluable patients.
• The mean age was 65.6 years (SD = 8.8 years).
• Of the sample, 51% were males and 49% were females.    
• Thirty percent of patients randomized had advanced cancer.
• The number of those completing the trial is not described.
• Types of cancer are not described.

The study was conducted in an unspecified single site in the United Kingdom.

• Patients were undergoing end-of-life care.
• The study has clincal applicability for end-of-life and palliative care.

The study was a randomized controlled trial.

A modified Borg scale was used.

• Twenty-nine percent in the intervention group and 41% in the control group initially randomized died before completion of the study, and missing data across groups were an average of 55%. 
• After two months, no significant differences in outcomes were seen between groups.
• Of 23 patients in the intervention group at two months, 9 considered it helpful and 14 did not. 
• Power analysis showed that sample size at two months was sufficient to detect an effect size of 2.5, but the actual effect size seen was .08, showing no meaningful effect.

This study shows that use of a handheld fan for breathlessness was not effective.

• The study had a small sample size of less than 100.
• The control condition used may not have been useful . 
• This study demonstrates the difficulty in providing an appropriate control condition with nonpharmaceutical types of interventions and the difficulty in attempting to evaluate longer term results in patients with advanced disease.  
   

Findings do not show any benefit of a handheld fan to help patients with the sensation of breathlessness.